Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock Holdings Reduced by AGF Management Ltd.

AGF Management Ltd. reduced its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 7.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 87,867 shares of the company’s stock after selling 6,758 shares during the period. AGF Management Ltd. owned 0.06% of Ionis Pharmaceuticals worth $3,605,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Raymond James Financial Services Advisors Inc. raised its holdings in shares of Ionis Pharmaceuticals by 3.3% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 50,585 shares of the company’s stock valued at $1,874,000 after buying an additional 1,604 shares during the last quarter. American Century Companies Inc. acquired a new stake in Ionis Pharmaceuticals in the first quarter worth $207,000. US Bancorp DE lifted its holdings in Ionis Pharmaceuticals by 12.3% during the first quarter. US Bancorp DE now owns 21,458 shares of the company’s stock worth $795,000 after acquiring an additional 2,343 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Ionis Pharmaceuticals by 9.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 9,662 shares of the company’s stock valued at $358,000 after purchasing an additional 831 shares in the last quarter. Finally, MetLife Investment Management LLC acquired a new stake in shares of Ionis Pharmaceuticals during the first quarter worth $318,000. Institutional investors own 93.86% of the company’s stock.

Insider Transactions at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, Director B Lynne Parshall sold 10,000 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Tuesday, September 26th. The shares were sold at an average price of $45.13, for a total transaction of $451,300.00. Following the completion of the sale, the director now directly owns 82,588 shares in the company, valued at approximately $3,727,196.44. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, Director B Lynne Parshall sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 26th. The stock was sold at an average price of $45.13, for a total transaction of $451,300.00. Following the completion of the transaction, the director now directly owns 82,588 shares of the company’s stock, valued at approximately $3,727,196.44. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP C Frank Bennett sold 4,460 shares of the company’s stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $46.50, for a total transaction of $207,390.00. Following the transaction, the executive vice president now owns 65,754 shares of the company’s stock, valued at approximately $3,057,561. The disclosure for this sale can be found here. Over the last three months, insiders have sold 18,282 shares of company stock valued at $834,603. Corporate insiders own 2.65% of the company’s stock.

Ionis Pharmaceuticals Stock Performance

Shares of NASDAQ:IONS opened at $49.77 on Thursday. The firm has a market cap of $7.14 billion, a PE ratio of -17.34 and a beta of 0.46. The company has a debt-to-equity ratio of 4.06, a quick ratio of 6.33 and a current ratio of 6.39. Ionis Pharmaceuticals, Inc. has a one year low of $32.69 and a one year high of $50.39. The firm’s 50 day simple moving average is $45.24 and its 200-day simple moving average is $41.80.

Analyst Ratings Changes

Several analysts have weighed in on IONS shares. Needham & Company LLC reiterated a “buy” rating and issued a $60.00 price objective on shares of Ionis Pharmaceuticals in a research note on Wednesday, September 27th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $65.00 price target on shares of Ionis Pharmaceuticals in a research note on Thursday, October 5th. Raymond James assumed coverage on Ionis Pharmaceuticals in a report on Thursday, September 28th. They issued a “strong-buy” rating and a $63.00 target price on the stock. William Blair reaffirmed an “outperform” rating on shares of Ionis Pharmaceuticals in a research report on Monday. Finally, Citigroup upgraded shares of Ionis Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price objective for the company from $36.00 to $60.00 in a research note on Monday, July 31st. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Ionis Pharmaceuticals has an average rating of “Hold” and an average target price of $48.23.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.